Clinical Trials Directory

Trials / Unknown

UnknownNCT04325126

Retinol-binding Protein 4 (RBP4) Metabolizm in Type 2 Diabetes Progression and Associated Cardiovascular Complications

Status
Unknown
Phase
Study type
Observational
Enrollment
500 (estimated)
Sponsor
First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Accepted

Summary

Retinol-binding protein 4 (RBP4) may affects obesity development and the development of obesity-related diseases including insulin resistance, type 2 diabetes, steatohepatitis and cardiovascular disease. This study aims to examine the involvement of RBP4 in patients with diagnosed diabetes, diabetic cardiovascular disease, pre-diabetes (pre-DM) and healthy controls during the progression of T2DM, and to evaluate the ability of RBP4 to predict cases of diabetes with an elevated risk of cardiovascular complications . Along with animal experiment.

Detailed description

A total of 500 Chinese patients admitted to the First Affliated Hospital of Xi'an Jiaotong University (Xi'an, China) between March 2020 and March 2022 were recruited to investigate the RBP4 profles. Peripheral blood samples are drawn at the initial medical examination, in the morning after a fast of at least 8 h, and immediately stored at -80˚C until the sphingolipid measurements were performed. Blood pressure, WC, hip circumference (HC), body weight and body height were measured by a trained physician. The participants enrolled in the study provided written informed consent.

Conditions

Interventions

TypeNameDescription
OTHERExposure factorsExposure factors,such as diet,exercise,environment

Timeline

Start date
2020-04-01
Primary completion
2022-12-01
Completion
2023-01-01
First posted
2020-03-27
Last updated
2022-12-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04325126. Inclusion in this directory is not an endorsement.